Clinical Trials Browser

Has results × AZD4547 × Clear all

NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 4 charts

Carcinoma, Non-Small-Cell Lung

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT01791985 2022-08-22

RADICAL

Phase 1/2 Completed

52 enrolled 17 charts

Breast Neoplasms

NCT04439240 2021-06-29

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Phase 2 Completed

52 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

43 enrolled 15 charts

FGFR1 Gene Amplification

NCT00979134 2019-03-15

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Phase 1 Terminated

95 enrolled 19 charts

Neoplasms

NCT01457846 2017-03-07

SHINE

Phase 2 Terminated

960 enrolled 13 charts

Gastrointestinal

Stomach Neoplasms

NCT01202591 2016-02-11

GLOW

Phase 1/2 Completed

127 enrolled 8 charts

Breast Neoplasms